Numerous animal models have provided substantial evidence demonstrating that inhibiting ferroptosis exerts significant effects

The gap

Evidence profile

Sourced from the future work and recommendations and conclusions of the source papers, classified as general, drawn from work published between 2024 and 2026, spanning 5 journals. Those papers have been cited 79 times in total.

Supporting evidence — 8 representative gaps

• Anti-cancer mechanism of traditional Chinese medicine natural products targeting ferroptosis (2026) · Chinese Medicine · doi

  To fully realize the clinical potential of natural prod- ucts in modulating ferroptosis, future research should focus on several key areas. First, the field must pro- gress from merely cataloging natural products towards mechanistic deepening and structural optimization. A dedicated effort to investigate the structure–activity relationships (SAR) of these agents is urgently needed. Future studies should focus on identifying the essential pharmacophores for ferroptosis induction and employ- ing chemical modifications to enhance efficacy, reduce off-target effects, and improve drug-like properties. Sec- ond, as research on single-agent TCM-derived products advances, the critical next step is to address their clinical translation. Key questions must be answered: How can we rationally design clinical trials to evaluate the synergy between TCM-derived ferroptosis inducers (including their optimized formulations) and standard therapies such as chemotherapy, radiotherapy, or immune check- point inhibitors? Furthermore, what reliable biomark- ers, such as those derived from lipid peroxidation, GPX4 activity, or iron metabolism, can be developed to predict and monitor patient responses to these therapies? Third, while research on single agents is progressing, investiga- tions into multi-component TCM formulas capable of inducing tumor ferroptosis remain limited. This gap may stem from the complexity of tumor pathogenesis and the current lack of well-defined, ferroptosis-targeting for- mulas. Future exploration in this area could be signifi- cantly informed by the accumulated clinical experience of renowned senior TCM practitioners, offering a unique systems-based approach to modulating ferroptosis.

  generalfuture work
  Keywords: ferroptosis clinical future derived natural modulating focus must products activity agents single therapies tumor fully
• Ferroptosis: an emerging key mechanism linking aging, surgical and anesthetic exposure to postoperative cognitive dysfunction (2026) · Frontiers in Immunology · doi

  Based on the understanding of ferroptosis’s core role in POCD pathogenesis, intervention strategies targeting different nodes of the ferroptosis pathway hold considerable therapeutic promise. However, nearly all of these strategies are at the preclinical stage, and their translation to clinical practice faces significant hurdles. 5.1 Targeting iron metabolism: iron chelators Iron chelators, which bind and sequester excess intracellular free iron, thereby cutting off the substrate for the Fenton reaction at its source, represent a classic strategy for directly inhibiting ferroptosis. Deferoxamine (DFO), a first-generation iron chelator, has demonstrated neuroprotective effects in several POCD-related models. Li et al. found that aged mice undergoing abdominal

  generalfuture work
  Keywords: iron ferroptosis pocd strategies targeting chelators based understanding core role pathogenesis intervention different nodes pathway
• Ferroptosis: an emerging key mechanism linking aging, surgical and anesthetic exposure to postoperative cognitive dysfunction (2026) · Frontiers in Immunology · doi

  (60, 63–65, 130, 132, 133) certain anesthetics provide the precipitating triggers. The protective effects of iron chelators, lipophilic antioxidants, and Nrf2-activating natural products in preclinical POCD models lend support to this concept. However, these observations remain largely correlative, and a critical unresolved question persists: does ferroptosis act as a proximal executor of synaptic damage and neuronal death, or is it merely a terminal removal mechanism for neurons already ren- dered non-functional by neuroinflammation and metabolic stress? Addressing this central question requires several lines of investiga- tion. First, temporally resolved studies are needed to determine whether lipid peroxidation and GPX4 inactivation precede or follow synaptic failure and microglial activation in the hours to days after surgery. Second, neuron-specific conditional knockout models (e.g., Gpx4 or Acsl4 deletion restricted to hippocampal neurons) should be employed to test whether blocking ferroptosis at the genetic level prevents POCD independently of anti-inflammatory effects. Third, the field must clarify which cell types—neurons, astrocytes, microglia, or oligodendrocytes— are the primary sites of ferroptotic damage, and whether intercellular propagation of lipid peroxides contributes to disease progression. Equally important are the translational challenges. Reliable biomarkers that can distinguish ferroptosis from other forms of oxidative injury in living patients are currently lacking. While QSM and T2 MRI can quantify regional brain iron content, and candidate lipid peroxidation products such as 15-HpETE-PE can be measured in cerebrospinal fluid, none has been prospectively validated for POCD risk stratification. Future clinical studies should integrate multimodal biomarkers—neuroimaging, CSF analysis, and blood- based assays—to construct predictive models and to monitor target engagement during therapeutic trials. Furthermore, key questions regarding therapeutic intervention remain unanswered: Is there a critical temporal window beyond which anti-ferroptotic therapy becomes futile? Would combining ferroptosis inhibitors with anti- inflammatory agents yield synergistic benefits, or merely add toxicity? Can BBB-penetrant iron chelators or GPX4 activators be safely administered to frail elderly surgical patients without com- promising systemic iron homeostasis or wound healing? Answers to these questions will determine whether ferroptosis-targeted thera- pies can progress from promising preclinical candidates to clinically meaningful interventions. Ultimately, the ferroptosis-centric model of POCD represents an exciting but still developing framework. The uncertainties outlined above should not be viewed as weaknesses of the hypoth- esis, but rather as guideposts for the next generation of mechanistic and translational research. It is only through carefully designed studies that directly test causality, establish temporal dynamics, and bridge the gap between animal models and human disease that the true role of ferroptosis in POCD will be elucidated—and its therapeutic potential realized.

  generalrecommendations
  Keywords: ferroptosis pocd iron models whether neurons lipid anti therapeutic effects chelators products preclinical remain critical
• Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine (2026) · Bone Research · doi

  OA is increasingly recognized as a complex, multifactorial disease that extends beyond mere cartilage degradation to involve the entire joint structure, including subchondral bone, synovium, and surround- ing tissues. Despite significant advancements in our understanding of OA pathophysiology, including the identification of key molecular pathways and genetic factors, considerable gaps remain in elucidating the precise mechanisms underlying disease initiation and progression. The aging population globally, particularly in regions such as China, where projections indicate that nearly 22% of the population will be over 65 by 2033, underscores the urgent need for effective therapeutic strategies to manage OA.1 Currently, there is no approved DMOAD that can halt or reverse the progression of OA. Recent research has discovered various pathways involved in OA, including inflammation, cartilage metabolism, and subchondral bone remodeling. These insights pave the way for the development of novel therapeutic agents that could potentially modify disease progression rather than merely alleviating symptoms. However, the heterogeneity inherent in OA complicates treatment strategies; a one-size-fits-all approach is unlikely to be effective. Instead, there is a growing consensus on the need for personalized medicine approaches that consider individual patient characteristics, including genetic profiles and specific OA phenotypes.

  generalfuture work
  Keywords: including disease progression cartilage subchondral bone pathways genetic population need effective therapeutic strategies there increasingly
• Inhibition or induction of gastrointestinal tumors by ferroptosis and intervention by herbal extracts (Review) (2026) · Oncology Letters · doi

  Ferroptosis has emerged as an important mechanism linking iron metabolism, lipid peroxidation, antioxidant defense and therapeutic response in GI tumors; its biological impact is highly context dependent. When oxidative lipid damage exceeds cellular defense capacity, ferroptosis can suppress tumor growth and enhance sensitivity to chemotherapy, radio‑ therapy, targeted therapy and immunotherapy. Conversely, incomplete or sublethal ferroptotic stress may activate compen‑ satory redox programs and promote treatment resistance. Thus, ferroptosis should not be viewed as uniformly antitumor or protumor, but rather as a dynamic process shaped by tumor genotype, metabolic state, microenvironmental support and therapeutic pressure. Herbal extracts and natural compounds provide a promising source of ferroptosis‑modulating agents, partly due to their multi‑target properties. However, current evidence remains largely preclinical, and several key issues, including mecha‑ nistic specificity, bioavailability, standardization, safety and reproducibility, must be addressed before clinical application. Future research should integrate rigorous ferroptosis valida‑ tion with pharmacological optimization, clinically relevant disease models, and biomarker‑guided combination strategies. A deeper understanding of ferroptosis regulation within the tumor‑stroma‑immune axis will be essential for translating experimental findings into clinical benefit and developing more precise therapeutic approaches for GI malignancies. By shifting from descriptive observations to context‑driven thera‑ peutic design, ferroptosis‑targeted strategies may contribute to more precise and effective interventions for GI malignancies.

  generalfuture work
  Keywords: ferroptosis therapeutic tumor lipid defense context therapy targeted clinical strategies precise malignancies emerged important mechanism
• Ferroptosis in osteoarthritis: metabolic reprogramming, immunometabolic crosstalk, and targeted intervention strategies (2025) · Frontiers in Immunology · cited 28× · doi

  Having delineated the pathophysiological links between OA and ferroptosis, we now examine current and emerging therapeutic approaches that aim to block or mitigate ferroptosis and potentially preserve joint integrity. Drawing upon prior discussions on the relationship between OA and ferroptosis, blocking or slowing ferroptosis holds promise for protecting cartilage, reducing synovitis, and improving joint function. Given the highly complex mechanisms of ferroptosis and the fact that OA pathology often involves multiple dysregulated pathways, an integrated, multifaceted treatment approach is required. In this section, we explore potential therapeutic strategies reported to date, discussing their practical applications and limitations in OA, and then offer prospects for future investigations. 5.1 Intervention strategies 5.1.1 Targeting iron homeostasis Iron chelators such as deferoxamine, deferiprone, and deferasirox bind free ferrous iron (Fe2+), reducing substrate availability for the Fenton reaction and thereby curtailing the lipid peroxidation cascade (152). Animal studies suggest that local or systemic use of deferoxamine may significantly alleviate OA cartilage degradation and inhibit ferroptosis markers in chondrocytes by activating the Nrf2 pathway (54). However, prolonged use of iron chelators might disrupt normal hematopoiesis and iron utilization, necessitating further safety and efficacy assessments in clinical settings (Table 1) (168, 169). Modulating TfR1 or enhancing FPN function can also curb ferroptosis by adjusting iron homeostasis. Inhibiting TfR1 reduces cellular iron uptake from the outset, lowering ferroptosis risk. Related inhibitors, explored extensively in oncology, remain in early-stage OA studies. For example, the TfR1 inhibitor Ferstatin II significantly suppresses TfR1 activity in vitro and in vivo, improving cartilage degradation. In post-DMM mouse models of traumatic OA, TfR1 expression is elevated in cartilage and fosters inflammation. Silencing TfR1 not only reduces chondrocytic iron content and oxidative stress but also promotes mitophagy and inhibits the mtDNA/cGAS/STING inflammatory axis, thereby breaking the cycle between ferroptosis and immune activation. A hydrogel microsphere with micelle microfluidic properties contains a ketone enol thiol-bridged nanoscale secondary structure, which downregulates TfR1 expression through metal chelation and increases the expression of CDGSH iron sulfur domain- containing protein 1 (CISD1), thereby restoring mitochondrial iron homeostasis and promoting cartilage repair (170). In the realm of natural compounds, biochanin A (BCA), extracted from Astragalus, protects against bone loss by inhibiting TfR1 and enhancing FPN, thereby reducing intracellular iron levels. It also targets the Nrf2/System Xc−/GPX4 pathway to remove free radicals and prevent lipid peroxidation. Micro-CT and histological staining of knee joints show that BCA prevents cartilage iron deposition and reduces KOA severity in iron-overloaded mice, suggesting new therapeutic avenues for KOA (171). 5.1.2 Antioxidants and inhibitors of lipid peroxidation GPX4 activators and ROS scavengers effectively suppress ferroptosis. Since GPX4 is critical for neutralizing lipid peroxides, enhancing GPX4 function or ensuring an ample supply of its substrate GSH can significantly lower ferroptosis incidence. Several small molecules and protein-based compounds are under development to modulate GPX4 enzyme activity. Icariin (ICA) can

  generalfuture work
  Keywords: iron ferroptosis cartilage thereby lipid therapeutic reducing function homeostasis peroxidation signi cantly enhancing reduces expression
• Broadening horizons: the multifaceted role of ferroptosis in breast cancer (2024) · Frontiers in Immunology · cited 24× · doi

  Ferroptosis is an interconnected network involving iron, selenium, amino acids, lipids, and redox chemistry, all of which play crucial roles in both physiological and pathological processes. As research into ferroptosis deepens, it has become evident that this network contributes significantly to the initiation, progression, invasion, and metastasis of breast cancer. This review summarizes the latest advances in understanding the molecular mechanisms related to ferroptosis in breast cancer, expanding our knowledge of the associated signaling and metabolic pathways involved in its pathology. Furthermore, with the growing identification of key molecular targets and regulatory mechanisms, such as gene transcription regulation and post-translational modifications involved in ferroptosis, targeting various aspects of this process may present novel therapeutic opportunities for breast cancer treatment. Current research suggests that ferroptosis exerts a dual effect on breast cancer, both promoting its development and serving as a potential therapeutic target to inhibit tumor progression. Ferritinophagy, a key pathway for releasing free iron within cells, plays a crucial role in promoting ferroptosis by producing excess iron ions. However, further research is needed to fully elucidate the mechanisms of ferritinophagy in breast cancer. Additionally, many known ferroptosis-related targets have yet to be directly validated in breast cancer models. Future research should focus on investigating how ferroptosis affects various immune cells, such as neutrophils and macrophages from the innate immune system, and T cells and B cells from the adaptive immune system within the tumor microenvironment. This could offer insights into new therapeutic strategies and prevention methods for breast cancer. Another key area of interest lies in identifying definitive biomarkers for ferroptosis. Although lipid peroxidation, iron accumulation, ROS, GPX4 expression, and cell viability have been proposed as indicators of ferroptosis, no specific biomarkers have been confirmed to date. While other forms of programmed cell death have well-defined markers, finding distinct biomarkers for ferroptosis would greatly enhance our understanding of its biological role. Despite significant advances in understanding ferroptosis regulation, the exact mechanisms by which cells undergo death remain unclear. The furthest downstream step identified so far involves the uncontrolled peroxidation of polyunsaturated fatty acid-containing phospholipids (PUFA-PLs), which may lead to membrane damage or rupture, compromising membrane integrity. Interestingly, recent studies suggest phospholipids with two PUFA tails are more effective in driving ferroptosis, hinting that lipid crosslinking might contribute to membrane damage. Clarifying the precise mechanisms through which ferroptosis leads to cell death will be a major focus in the coming years. Furthermore, the interplay between inflammation and ferroptosis

  generalfuture work
  Keywords: ferroptosis breast cancer mechanisms cells iron understanding therapeutic immune biomarkers cell death membrane network crucial
• Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding (2024) · Frontiers in Endocrinology · cited 27× · doi

  Although numerous animal models have provided substantial evidence demonstrating that inhibiting ferroptosis exerts significant effects on NAFLD/NASH, their precise mechanisms remain elusive. Furthermore, clinical research investigating pharmacological therapies aimed at inhibiting ferroptosis for treating NAFLD/NASH is currently lacking. NAFLD/NASH has emerged as a critical public health concern, necessitating further investigation into its underlying mechanisms and treatment strategies.

  generalconclusions
  Keywords: nafld nash inhibiting ferroptosis mechanisms numerous animal models provided substantial evidence demonstrating exerts signi cant

Questions about this gap